Date: 2016-02-02
Type of information: Collaboration agreement
Compound: rare monoclonal antibodies
Company: Teva Pharmaceutical Industries (Israel) AbCellera (Canada)
Therapeutic area: Technology - Services
Type agreement: collaboration R&D
Action mechanism: monoclonal antibody
Disease:
Details: * On February 2, 2016, Teva Pharmaceutical Industries and AbCellera have entered into a collaborative research agreement whereby AbCellera will apply its high-throughput single cell antibody platform for the discovery of rare monoclonal antibodies. Under the terms of the agreement, AbCellera will receive an upfront payment, research payments, and is eligible to receive undisclosed downstream milestones associated with the development and approval of therapeutic antibodies.
Financial terms:
Latest news:
